Literature DB >> 6896455

Clonal variation in the sensitivity of B16 melanoma to m-AMSA.

T C Stephens, J H Peacock.   

Abstract

A hypothesis that m-AMSA may have greater cytotoxicity in melanin-containing tumour tissues, because it may reversibly bind to melanin, leading to prolonged drug exposure, was examined. Clonal lines of B16 melanoma which differed widely in pigmentation level were selected by isolating artificial lung colonies and in vitro soft-agar colonies, and implanting them into mice. Excision cell-survival assays performed 24 h after drug administration showed that in vivo sensitivity to m-AMSA progressively increased as pigmentation level decreased, but that m-AMSA drug levels measured 24 h after treatment were much lower in amelanotic than in melanotic lines. In dose-survival studies the reduced sensitivity of melanotic cell lines was revealed as a large shoulder (Dq = 27 mg/kg) though the terminal slopes for melanotic and amelanotic cell lines were similar (D10 approximately 31 mg/kg). Time-course studies indicated that there was no significant loss of drug from a melanotic cell line for 72 h after drug administration, though in an amelanotic cell line drug levels fell 10-fold in 10 h. There was, however, no evidence for prolonged drug cytotoxicity in the melanotic cell line. Using a fractionated drug-treatment regime, the greater cytotoxicity of m-AMSA to amelanotic tumour tissue was confirmed in a non-invasive regrowth-delay assay.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6896455      PMCID: PMC2011041          DOI: 10.1038/bjc.1982.133

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  13 in total

1.  A fluorescence assay for 4'-(9-acridinylamino)methanesulfon-m-anisidide, a new antitumor agent.

Authors:  P E Gormley; R L Cysyk
Journal:  Anal Biochem       Date:  1979-07-15       Impact factor: 3.365

2.  Stem-cell survival and tumor control in the Lewis lung carcinoma.

Authors:  G G Steel; K Adams
Journal:  Cancer Res       Date:  1975-06       Impact factor: 12.701

3.  Selective localization of 4'-(9-acridinylamino)-methanesulfon-m-anisidide in B 16 melanoma.

Authors:  D D Shoemaker; S S Legha; R L Cysyk
Journal:  Pharmacology       Date:  1978       Impact factor: 2.547

4.  Potential antitumor agents. 14. Acridylmethanesulfonanilides.

Authors:  B F Cain; R N Seelye; G J Atwell
Journal:  J Med Chem       Date:  1974-09       Impact factor: 7.446

5.  The lung-colony assay: extension to the Lewis lung tumour and the B16 melanoma--radiosensitivity of B16 melanoma cells.

Authors:  R P Hill; J A Stanley
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1975-04

6.  The experimental antitumour properties of three congeners of the acridylmethanesulphonanilide (AMSA) series.

Authors:  B F Cain; G J Atwell
Journal:  Eur J Cancer       Date:  1974-08       Impact factor: 9.162

7.  Interaction of 4'-(9-acridinylamino)methanesulfon-m-anisidide with DNA and inhibition of oncornavirus reverse transcriptase and cellular nucleic acid polymerases.

Authors:  P E Gormley; V S Sethi; R L Cysyk
Journal:  Cancer Res       Date:  1978-05       Impact factor: 12.701

8.  A soft agar colony assay for Lewis lung tumour and B16 melanoma taken directly from the mouse.

Authors:  V D Courtenay
Journal:  Br J Cancer       Date:  1976-07       Impact factor: 7.640

9.  Cell yield and cell survival following chemotherapy of the B16 melanoma.

Authors:  T C Stephens; J H Peacock
Journal:  Br J Cancer       Date:  1978-11       Impact factor: 7.640

10.  Repopulation of gamma-irradiated Lewis lung carcinoma by malignant cells and host macrophage progenitors.

Authors:  T C Stephens; G A Currie; J H Peacock
Journal:  Br J Cancer       Date:  1978-11       Impact factor: 7.640

View more
  6 in total

1.  A comparison of adriamycin and mAMSA. II. Studies with V79 and human tumour multicellular spheroids.

Authors:  C M West; I J Stratford
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

2.  High uptake of RSU 1069 and its analogues melanotic melanomas.

Authors:  J M Walling; J Deacon; S Holliday; I J Stratford
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Development of drug resistance in a murine mammary tumour.

Authors:  T J McMillan; T C Stephens; G G Steel
Journal:  Br J Cancer       Date:  1985-12       Impact factor: 7.640

4.  Relationship between the melanin content of a human melanoma cell line and its radiosensitivity and uptake of pimonidazole.

Authors:  R el Gamoussi; M D Threadgill; M Prade; I J Stratford; M Guichard
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Clonal variation in the sensitivity of a murine mammary carcinoma to melphalan.

Authors:  T J McMillan; T C Stephens; G G Steel
Journal:  Br J Cancer       Date:  1986-06       Impact factor: 7.640

6.  Novel therapeutic compound acridine-retrotuftsin action on biological forms of melanoma and neuroblastoma.

Authors:  Miroslawa Cichorek; Anna Ronowska; Monika Gensicka-Kowalewska; Milena Deptula; Iwona Pelikant-Malecka; Krystyna Dzierzbicka
Journal:  J Cancer Res Clin Oncol       Date:  2018-10-26       Impact factor: 4.553

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.